Fremanezumab for preventive treatment of migraine: Functional status on headache-free days

Juliana VanderPluym, David W Dodick, Richard B Lipton, Yuju Ma, Pippa S Loupe, Marcelo E Bigal, Juliana VanderPluym, David W Dodick, Richard B Lipton, Yuju Ma, Pippa S Loupe, Marcelo E Bigal

Abstract

Objective: To evaluate the effect of fremanezumab on the functional status on headache-free days in phase 2 episodic migraine (EM) and chronic migraine (CM) studies.

Methods: Functional status data were collected prospectively via the electronic headache diary on all headache-free days by patients answering questions regarding work/school/household chore performance, speed of work completion, concentration, and feeling of fatigue. Individuals with EM receiving monthly doses of fremanezumab 225 mg (n = 96) or 675 mg (n = 97) or placebo (n = 104) were compared. Individuals with CM receiving fremanezumab 675 mg followed by monthly 225 mg (n = 88) and 900 mg (n = 86) were also independently compared to those receiving placebo (n = 89).

Results: In patients with EM, compared to patients receiving placebo, those receiving fremanezumab experienced an increased number of headache-free days with normal function in work/school/household chore performance and concentration/mental fatigue measures compared to their baseline over the entire treatment period (all p < 0.005). An increased number of headache-free days with normal functional performance for some measures was also found in the CM group in those treated with fremanezumab.

Conclusion: There was an increased number of headache-free days with normal functional performance on all measures for the patients with EM and some measures for patients with CM in the fremanezumab-treated groups. Further research is required to confirm these findings in a prospective study and to clarify the underlying mechanism(s).

Clinicaltrialsgov identifier: NCT02025556 and NCT02021773.

Classification of evidence: This study provides Class II evidence that for patients with migraine, fremanezumab increases normal functional performance on headache-free days.

Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Figures

Figure 1. Patient responses to questions concerning…
Figure 1. Patient responses to questions concerning work/school/chore performance
(A) Work/school performance: I worked/studied normally. (B) Best describe your ability to perform household chores: I performed household chores normally. CM = chronic migraine; HFEM = high-frequency episodic migraine. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 2. Patient responses to questions on…
Figure 2. Patient responses to questions on having difficulty in concentration and mental fatigue
(A) How much time did you feel that you were working more slowly or taking longer to complete a task? None of the time. (B) How much of the time yesterday did you find it difficult to concentrate on what you needed to do? None of the time. (C) On average, how much of the time yesterday were you very tired, asleep, or feeling drained? None of the time. CM = chronic migraine; HFEM = high-frequency episodic migraine. *p < 0.05, **p < 0.01, ***p < 0.001.

References

    1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646–657.
    1. Buse DC, Manack AN, Fanning KM, et al. . Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012;52:1456–1470.
    1. Natoli JL, Manack A, Dean B, et al. . Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30:599–609.
    1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd Edition (Beta Version). Cephalalgia 2013;33:629–808.
    1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545–1602.
    1. Lampl C, Thomas H, Stovner LJ, et al. . Interictal burden attributable to episodic headache: findings from the Eurolight project. J Headache Pain 2016;17:9.
    1. Coppola G, Pierelli F, Schoenen J. Habituation and migraine. Neurobiol Learn Mem 2009;92:249–259.
    1. Blau JN. Migraine prodromes separated from the aura: complete migraine. Br Med J 1980;281:658–660.
    1. Blau JN. Migraine postdromes: symptoms after attacks. Cephalalgia 1991;11:229–231.
    1. Maniyar FH, Sprenger T, Monteith T, Schankin CJ, Goadsby PJ. The premonitory phase of migraine: what can we learn from it? Headache 2015;55:609–620.
    1. Giffin NJ, Ruggiero L, Lipton RB, et al. . Premonitory symptoms in migraine: an electronic diary study. Neurology 2003;60:935–940.
    1. Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ. The migraine postdrome: an electronic diary study. Neurology 2016;87:309–313.
    1. Bigal ME, Dodick DW, Rapoport AM, et al. . Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015;14:1081–1090.
    1. Bigal ME, Edvinsson L, Rapoport AM, et al. . Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015;14:1091–1100.
    1. Silberstein SD, Dodick DW, Bigal MEet al. . Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017;377:2113–2122.
    1. Bigal M, Dodick D, Krymchantowski AV, et al. . TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology 2016;87:1–8.
    1. Aycardi E, Bigal M, McDonald M. Fremanezumab (formerly TEV-48125) reduces headache pain within the first week of beginning treatment in the phase 2 episodic migraine study: presented at the American Headache Society abstract IOR5. Headache 2017;57(suppl 3):I29.
    1. US Department of Health and Human Services Food and Drug Administration. Multiple endpoints in clinical trials guidance for industry draft guidance. 2017. Available at: . Accessed May 15, 2018.
    1. Silberstein SD. Topiramate in migraine prevention: a 2016 perspective. Headache 2017;57:165–178.
    1. Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 2014;20:22–33.
    1. Peres MF, Mercante JP, Guendler VZ, et al. . Cephalalgiaphobia: a possible specific phobia of illness. J Headache Pain 2007;14:56–59.
    1. Giannini G, Zanigni S, Grimaldi D, et al. . Cephalalgiaphobia as a feature of high-frequency migraine: a pilot study. J Headache Pain 2013;14:49.
    1. Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ. Brain activations in the premonitory phase of nitroglycerin triggered migraine attacks. Brain 2014;137:232–242.
    1. Eftekhari S, Salvatore CA, Johansson S, Chen T, Zeng Z, Edvinsson L. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion: relation to the blood-brain barrier. Brain Res 2015;1600:93–109.
    1. Goldberg SW, Siberstein SD. Targeting CGRP: a new era for migraine treatment. CNS Drugs 2015;29:443–452.
    1. Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache 2009;49:1258–1266.
    1. Cernuda-Morollon E, Ramon C, Martinez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 2015;156:820–824.
    1. Shao B, Zhou YL, Wang H, Lin YS. The role of calcitonin gene-related peptide in post-stroke depression in chronic mild stress-treated ischemic rats. Physiol Behav 2015;139:224–230.
    1. Sink KS, Walker DL, Yang Y, Davis M. Calcitonin gene-related peptide in the bed nucleus of the stria terminalis produces an anxiety-like pattern of behavior and increases neural activation in anxiety-related structures. J Neurosci 2011;31:1802–1810.
    1. Schorscher-Petcu A, Austin JS, Mogil JS, Quirion R. Role of central calcitonin gene-related peptide (CGRP) in locomotor and anxiety- and depression-like behaviors in two mouse strains exhibiting a CGRP-dependent difference in thermal pain sensitivity. J Mol Neurosci 2009;39:125–136.
    1. Gungor NZ, Pare D. CGRP inhibits neurons of the bed nucleus of the stria terminalis: implications for the regulation of fear and anxiety. J Neurosci 2014:34:60–65.
    1. Vaeroy H, Sakurada T, Forre O, Kass E, Terenius L. Modulation of pain in fibromyalgia (fibrosis syndrome) cerebrospinal fluid (CSF): investigation of pain related neuropeptides with special reference to calcitonin gene-related peptide (CGRP). J Rheumatol 1989;16(suppl 19):94–97.
    1. Schou WS, Ashina S, Amin FM, Goadsby P, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain 2017;18:34.
    1. Evangelista S. Capsaicin receptor as target of calcitonin gene-related peptide in the gut. In: Abdel-Salam OME, editor. Capsaicin as a Therapeutic Molecule, Progress in Drug Research. vol 68. Basel: Springer; 2014.
    1. Burton WN, Landy SH, Downs KE, Runken C. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc 2009;84:436–445.
    1. Lipton RB, Rosen NL, Ailani J, DeGryse RE, Gillard PJ, Varon SF. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program. Cephalalgia 2016;36:899–908.
    1. Lipton RB, Varon SF, Grosberg B, et al. . OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011;77:1465–1472.
    1. Dodick DW, Turkel CC, DeGryse RE, et al. . Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. J Pain 2015;16:164–175.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel